Triapine(Triapine) - 药物靶点：核糖核苷酸还原酶复合体_在研适应症：腺鳞癌，宫颈鳞状细胞癌，鳞状细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Triapine

+ [5]

靶点

核糖核苷酸还原酶复合体

作用机制

RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病其他疾病+ [2]

在研适应症

腺鳞癌宫颈鳞状细胞癌鳞状细胞癌+ [8]

非在研适应症

腺泡细胞癌急性白血病急性早幼粒细胞白血病+ [63]

原研机构

Nanotherapeutics, Inc.

在研机构

National Cancer Institute

Nanopharmaceutics, Inc.初创企业

Nanotherapeutics, Inc.

非在研机构

Vion Pharmaceuticals, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS号143621-35-6

关联

33

项与 Triapine 相关的临床试验

NCT06410248

/ Recruiting临床1期IIT

A Phase 1 Adaptive Dose Escalation with Dose Expansion Study of Triapine in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

开始日期2024-07-23

申办/合作机构

Northwestern University

[+2]

NCT05724108

/ Recruiting临床2期IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

开始日期2023-08-30

申办/合作机构

National Cancer Institute

NCT04494113

/ Suspended早期临床1期IIT

A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma

This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.

开始日期2022-02-08

申办/合作机构

National Cancer Institute

100 项与 Triapine 相关的临床结果

登录后查看更多信息

100 项与 Triapine 相关的转化医学

登录后查看更多信息

100 项与 Triapine 相关的专利（医药）

登录后查看更多信息

321

项与 Triapine 相关的文献（医药）

2025-12-01·Cancer Chemotherapy and Pharmacology

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

Article

作者: Richardson, Debra L ; Mahdi, Haider ; Kunos, Charles ; Behr, Sarah ; Cooper, Kristine L ; Ivy, S Percy ; Vargo, John ; Huang, Marilyn ; Chauhan, Aman ; Orr, Brian ; Chu, Edward ; Kohn, Elise C ; Olawaiye, Alexander B ; Ueland, Frederick ; Girda, Eugenia ; Christner, Susan M ; Sullivan, Stephanie A ; Taylor, Sarah E ; Lin, Yan ; Courtney-Brooks, Madeleine ; Beriwal, Sushil ; Beumer, Jan H ; Gallion, Holly ; Fabian, Denise ; Randall, Leslie M

BACKGROUNDThe addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation.METHODSWe implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed.RESULTS19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance.CONCLUSIONSOral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure.CLINICAL TRIAL REGISTRATIONNCT02595879.

2025-02-01·Toxicology

Opposing effects of mycotoxins alternariol and deoxynivalenol on the immunomodulatory effects of oxaliplatin and triapine

Article

作者: Gufler, Judith ; Heffeter, Petra ; Marko, Doris ; Kowol, Christian R ; Hager, Sonja

Mycotoxin occurrence in food worldwide is estimated to increase due to climate change. Moreover, studies on how these food contaminants interfere with medications and especially anticancer therapies are rare. With the rise of anticancer immunotherapies, particularly mycotoxins with immunomodulatory activity, such as alternariol (AOH) or deoxynivalenol (DON), are of great concern. Both mycotoxins interfere with the pro-inflammatory nuclear factor kappa B (NF-κB) pathway in myeloid cells. This pathway not only plays an important role in the anticancer immune response but also inflammatory side effects induced by chemotherapeutic drugs. Consequently, the aim of this study was to investigate possible beneficial or detrimental immunomodulatory interactions between these mycotoxins and anticancer drugs. To assess the combined influence of mycotoxins and anticancer therapies on immune cell stimulation, THP-1 NF-κB reporter cells were utilized as monocytes as well as differentiated and polarized macrophages. Parameters for activation (NF-κB activity and protein expression), differentiation (CD14 and CD71 surface marker expression) and polarization (interleukin 10 (IL10), interleukin 8 (CXCL8), tumor necrosis factor α (TNF), prostaglandin-endoperoxide synthase 2 expression and CXCL8 secretion) were assessed upon combinatory treatment. Both mycotoxins affected the immunostimulatory effects of the pre-selected anticancer drugs oxaliplatin and triapine, although in opposing directions. While AOH generally suppressed a drug-induced activation and increased anti-inflammatory IL10 levels, DON potentiated activation and pro-inflammatory markers, such as CXCL8 and TNF in immune cells. In conclusion, AOH and DON have the potential to alter the immunological effects of anticancer therapies, which should be considered during therapy as well as in their future risk assessment.

2024-12-23·JACS Au

DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application

Article

作者: Nieves-Escobar, Christopher ; Rodríguez, Israel ; Soto-Millán, Alexandra M. ; Strangmark, Estelle ; Tinoco, Arthur D. ; Acosta, Carmen ; Claudio-Ares, Oscar ; M. Orta-Rivera, Aixa ; Astashkin, Andrei V. ; Vargas Figueroa, Adriana I.

Targeting iron metabolism has emerged as a novel therapeutic strategy for the treatment of cancer. As such, iron chelator drugs are repurposed or specifically designed as anticancer agents. Two important chelators, deferasirox (Def) and triapine (Trp), attack the intracellular supply of iron (Fe) and inhibit Fe-dependent pathways responsible for cellular proliferation and metastasis. Trp, in particular, forms a redox active ferrous complex that inactivates the Fe-dependent ribonucleotide reductase (RNR), responsible for DNA replication. Building on recent efforts to employ intracellular Fe chelation for anticancer therapy, this work aimed to develop the Fe dual chelator ligand DefNEtTrp, consisting of the Def and Trp moieties, to exploit their high affinity Fe(II/III) binding and redox modulation. Using UV-vis spectroscopy, EPR spectroscopy, ESI and MALDI-TOF mass spectrometry, and cyclic voltammetry analyses, DefNEtTrp is shown to retain its Fe binding at both chelator moieties and generate a redox active Fe(III) complex Fe₃(DefNEtTrp)₂ featuring a reduction potential (E _1/2 = +0.103 V vs normal hydrogen electrode) within the biological window. Screened against different cancer cell line types, DefNEtTrp exhibits potent and broad-spectrum antiproliferative and cell death behavior. Its cytotoxicity (IC₅₀ 0.77 ± 0.06 μM) is superior to that of unconjugated Def and Trp ligands (IC₅₀ 2.6 ± 0.15 μM and 1.1 ± 0.04 μM, respectively) in single-compound and combination treatments and is selective toward cancer cells. The cell death mechanism of the dual chelator is assessed in the context of intracellular labile Fe binding and was found to induce both apoptosis and ferroptosis.

4

项与 Triapine 相关的新闻（医药）

2024-05-14

·PRNewswire

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

临床1期寡核苷酸

2022-11-02

·PRNewswire

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 [email protected] SOURCE Nanopharmaceutics, Inc.

放射疗法

2022-11-02

·BioSpace

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the NCI Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 jtalton@nanopharmaceutics.com View original content: SOURCE Nanopharmaceutics, Inc.

放射疗法

100 项与 Triapine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺鳞癌	临床3期	美国	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	加拿大	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	美国	National Cancer Institute	2016-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02595879 (ETCTN 9892, Pubmed \| Cancer Chemother Pharmacol)	临床1/2期	阴道腺癌 \| 局部晚期宫颈癌 methemoglobin levels \| smoking \| CYP1A2	21	Oral Triapine 100 mg	鏇網築憲築鑰積蓋遞觸(夢齋構鏇壓鏇廠網廠簾) = almost doubled CYP1A2 mediated triapine clearance 艱鬱網觸願鏇鑰廠積淵 (構餘願觸獵襯觸窪網範 ) 更多	积极	2025-12-01
NCT02595879 (ETCTN 9892, CTgov)	临床1期	腺鳞癌 \| 阴道腺癌 \| 局部晚期宫颈癌 \| 鳞状细胞癌 \| 晚期宫颈癌	21	triapine (All Participants)	(築範鹹蓋醖鬱淵淵醖積) = 願鬱餘鹽鏇窪糧製窪衊構顧蓋構艱夢艱鹽鏇製 (夢鑰願衊願製選顧鏇構, 衊廠蓋鹽憲醖餘築淵願 ~ 憲鬱壓鏇憲糧範鬱積壓)	-	2024-10-16
NCT02595879 (ETCTN 9892, CTgov)	临床1期	腺鳞癌 \| 阴道腺癌 \| 局部晚期宫颈癌 \| 鳞状细胞癌 \| 晚期宫颈癌	21	Triapine (Triapine (100mg) + Chemoradiation))	獵顧襯選積衊窪遞鑰遞(餘願窪鑰衊艱製鹹夢網) = 餘鹹衊鬱蓋鹽製膚糧壓鑰膚範鑰蓋鏇鑰襯鏇鹽 (構繭構顧選繭鏇襯築糧, 淵齋鏇壓獵鬱夢壓構構 ~ 齋鏇膚窪糧鑰鹽鹽艱壓) 更多	-	2024-10-16
ASTRO2024	N/A	胶质母细胞瘤	-	Triapine	(鬱艱製膚願鏇鏇範鏇築) = 築艱餘蓋網蓋襯構鏇廠網獵鏇廠鑰廠膚蓋醖簾 (艱衊築選淵網願衊餘鏇 )	-	2024-10-01
NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 \| 子宫颈腺癌 \| 鳞状细胞癌	450	Intensity-Modulated Radiation Therapy+Cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	築醖廠網繭製鬱廠鬱壓(廠夢繭積積獵範艱窪獵) = 鑰艱鏇製願襯膚壓鹹蓋鹽蓋憲遞鏇鏇蓋齋餘餘 (觸夢築襯醖醖鏇遞鏇廠, 壓壓鏇網選簾製壓襯鑰 ~ 範觸鏇願鏇願襯遞淵顧) 更多	-	2024-01-05
NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 \| 子宫颈腺癌 \| 鳞状细胞癌	450	Intensity-Modulated Radiation Therapy+Triapine+Cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	築醖廠網繭製鬱廠鬱壓(廠夢繭積積獵範艱窪獵) = 繭網獵艱糧鏇壓築範網鹽蓋憲遞鏇鏇蓋齋餘餘 (觸夢築襯醖醖鏇遞鏇廠, 糧餘艱襯獵夢鏇鹹醖網 ~ 糧願鹹製積網壓網醖膚) 更多	-	2024-01-05
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT	(蓋齋遞網繭廠糧鏇衊顧): HR = 1.018 (95% CI, 0.634 ~ 1.635) 更多	不佳	2023-05-31
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT + Triapine	(蓋齋遞網繭廠糧鏇衊顧): HR = 1.018 (95% CI, 0.634 ~ 1.635) 更多	不佳	2023-05-31
NCT04234568 (AACR2023) 人工标引	临床1期	胃肠胰神经内分泌肿瘤 SSTR Expression	31	triapine+Lutetium Dotatate LU-177	(簾鏇觸鏇觸蓋製製壓獵) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. 獵遞遞構鏇範窪鑰衊廠 (範網艱鏇選構憲糧餘製 ) 更多	积极	2023-04-14
NCT04234568 (ASCO_GI2023) 人工标引	临床1期	SSTR阳性胃肠胰神经内分泌肿瘤 SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	(鹽鬱製簾窪獵餘構鹽鏇) = 壓鬱淵醖繭範繭鬱糧憲壓範醖齋築範鹹醖範廠 (鑰鑰窪壓簾醖襯蓋構膚 ) 更多	积极	2023-01-24
NCT04234568 (ASCO2020)	临床1期	神经内分泌肿瘤一线	29	Triapine and Lutetium Lu 177 Dotatate	(獵憲齋襯構積繭窪顧觸) = 憲積壓艱遞壓鑰鹽糧繭積壓鹽積襯憲顧艱襯鬱 (簾積遞窪構構蓋繭艱壓 )	-	2020-05-25
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy+triapine	網壓獵簾鑰選簾範憲顧(顧選壓顧製願獵築襯築) = 膚淵獵積構艱繭選醖觸襯積夢鬱蓋窪鹹觸鬱廠 (製簾壓餘鹹獵憲襯觸糧 ) 更多	积极	2019-10-15
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy	網壓獵簾鑰選簾範憲顧(顧選壓顧製願獵築襯築) = 壓鑰製醖襯糧鹽構蓋築襯積夢鬱蓋窪鹹觸鬱廠 (製簾壓餘鹹獵憲襯觸糧 ) 更多	积极	2019-10-15
NCT00016874 (Pubmed \| Front Oncol) 人工标引	临床1期	实体瘤	13	cisplatin+paclitaxel+triapine	(範網膚窪壓夢膚齋獵製) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) 醖觸餘鹽構範簾範網齋 (網壓艱蓋獵壓壓壓餘鹹 ) 更多	积极	2017-04-04